Solbec soars 70 per cent on cancer drug result
Tuesday, 23 November, 2004
Shares in Solbec Pharmaceuticals (ASX:SBP) jumped almost 70 per cent to $0.21 today after preliminary results from a study conducted by the Tumour Immunology Group at the University of Western Australia indicated that the company's cancer drug, Coramsine, was effective in treating and preventing mesothelioma in a mouse model of the cancer.
Mice treated with Coramsine in combination with the immune-triggering compound CpG -- a synthetic DNA fragment containing cytosine and guanine -- showed total remission of the mesothelioma. The therapy also seemed to confer lasting immunity against mesothelioma, as attempts to cause tumour formation in a treated, 'cured' mouse failed.
Coramsine is a mixture of two alkaloids from the prickly weed Solanum linneaum, also known as devil's apple.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
